Phase 3 N=274 Eslicarbazepine Acetate Monotherapy Long Term Study
Epilepsy
Primary: Number and Percent of Subjects With Treatment Emergent Adverse Events — 220 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue
Fatigue
Primary: Skeletal Muscle Fatigue as Measured by Biodex 4 Pro After 4 Weeks of Placebo — 59.69; 42.07; 67.17; 63.24 Newton-Meters
Phase 2 N=18 Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Immune Response Following Treatment — 6; 5 Participants
Phase 2 N=113 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) · Rhabdomyosarcoma · Leiomyosarcoma
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants
N/A N=30 Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash
Arthropathy of Hip · Arthropathy of Knee
Primary: Duration of Sensory Block — 3.41; 2.81; 3.23; 3.12 hours
Phase 3 N=119 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.2 percentage of participants
N/A N=101 Study Evaluating Pharmacovigilance Of Refacto AF
Hemophilia A
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 15; 59; 2; 7 participants
Phase 2 N=43 A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With an Objective Overall Response — 6.1 percentage of participants
N/A N=330 Reducing Offenders' HIV Risk: MI Enhanced Case Management With Drug-Free Housing
Alcohol and Drug Abuse
Primary: Change in Criminal Justice Outcomes — 66; 70; 83; 111 Participants
Phase 3 N=75 Treatment of Mania Symptoms With Drug Therapy
Bipolar Disorder · Schizophrenia
Primary: Symptoms of Mania, as Measured by Young Mania Rating Scale — 5.7; 11.1; 10.0 units on a scale
Phase 1 N=9 A Study of LY2584702 in Solid Tumors
Cancer
Primary: Number of Participants With Clinically Significant Effects — 0; 0 Participants
Phase 4 N=8 Sitagliptin Dose Determination Study
Diabetes Mellitus, Type 1
Primary: Better Targeted Blood Glucose Levels — 184.1; 179.4; 153.6; 181.5 mg/dl — p=0.003
Phase 1 N=41 A Study of LY3025876 in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug-related Adverse Events or Any Serious Adverse Events — 0; 0; 0; 0 participants
Phase 3 N=199 The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Infections, Papillomavirus
Primary: Number of Subjects Reporting Serious Adverse Events — 6; 2; 0 Participants
Phase 2 N=80 Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.
Bacterial Infection Due to Streptococcus, Group B · Streptococcus Agalactiae
Primary: Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61 — 100; 100; 100; 100 Percentage of subjects